FDA Warning Letter: Major Sterility, CAPA, Environmental Monitoring and CGMP Violations

The FDA Warning Letter reviewed in this article identifies significant Current Good Manufacturing Practice (CGMP) deficiencies at a pharmaceutical facility involved in the manufacture of sterile injectable drug products.

The inspection was conducted under the authority of the U.S. Food and Drug Administration (FDA) to protect patients from unsafe, ineffective, adulterated, or poor-quality medicines. FDA identified serious deficiencies involving:

Sterility failure investigations
Repeated fungal contamination
Environmental monitoring (EM)
Deviation and failure investigations
CAPA effectiveness
Quality Unit oversight
Aseptic processing
Airflow visualization studies
Restricted Access Barrier System (RABS) controls
Cleanroom maintenance
Disinfection effectiveness
Process validation
Cleaning validation
Batch documentation
Facility and equipment qualification
Pharmaceutical quality systems

The findings fall primarily under 21 CFR Parts 210 and 211, including 21 CFR 211.192, 211.22(d), 211.113(b), and 211.58.

The FDA Warning Letter demonstrates that sterile manufacturing facilities must maintain a robust contamination control strategy supported by scientifically sound investigations, effective CAPA, reliable environmental monitoring, qualified facilities, validated processes, and strong Quality Unit oversight.

Major Findings in the FDA Warning Letter

The inspection identified three major areas of concern:

Inadequate investigation of sterility failures and recurring fungal contamination.
Inadequate Quality Unit responsibilities and oversight.
Deficiencies in aseptic processing, environmental monitoring, airflow visualization, and facility maintenance.

These deficiencies were considered systemic and required comprehensive remediation rather than isolated procedural corrections.

1. Inadequate Investigation of Sterility Failures

Under 21 CFR 211.192, pharmaceutical manufacturers are required to thoroughly investigate unexplained discrepancies, batch failures, and failures of components to meet established specifications.

The facility was operating as a contract manufacturer of sterile injectable products and failed to adequately investigate a sterility test failure.

A fungal organism, Ustilago spermophora, was identified during testing.

Although the affected batch was rejected, FDA determined that the investigation was inadequate because the root cause was classified as “undetermined” without sufficiently investigating potential contamination pathways. Potential sources that should have been evaluated included:

Personnel movement
Material movement
HVAC systems
Airflow patterns
Facility design
Cleaning and disinfection
Equipment surfaces
Aseptic interventions
Environmental monitoring
Personnel practices
Potential fungal migration through classified areas

The FDA Warning Letter emphasized that rejecting a contaminated batch alone does not constitute an adequate investigation. The investigation must determine the probable root cause and establish effective CAPA to prevent recurrence.

2. Recurring Fungal Contamination in Aseptic Areas

One of the most significant issues identified in the FDA Warning Letter was repeated recovery of fungi from areas associated with sterile manufacturing.

FDA identified multiple environmental monitoring excursions involving fungal organisms. Examples described in the inspection included recoveries of organisms such as:

Chaetomium globosum
Didymella glomerata
Mycosphaerella africana
Chaetomium cruentum/globosum

The observations occurred at different locations and dates associated with aseptic filling operations. The repeated recovery of fungi raised concerns about the facility’s contamination control strategy.

3. Failure to Identify the Root Cause of Environmental Monitoring Excursions

FDA found that several investigations did not adequately identify the source of fungal contamination. In some cases, the company attributed contamination to events such as power failures.

However, FDA determined that the investigations did not sufficiently evaluate other possible contamination pathways. For sterile manufacturing, an investigation of an environmental monitoring excursion should consider:

Personnel Factors

Gowning practices
Personnel movement
Operator interventions
Personnel qualification
Aseptic technique

Facility Factors

HVAC performance
Air pressure differentials
Airflow patterns
Building condition
Room interfaces
Material transfer routes

Equipment Factors

Equipment design
Equipment cleaning
Equipment disinfection
Equipment maintenance
Difficult-to-clean areas

Process Factors

Manual interventions
Line stoppages
Equipment adjustments
Product exposure
Material transfers

The FDA Warning Letter makes clear that simply identifying an event that occurred around the same time as an environmental monitoring excursion is not sufficient to establish a scientifically justified root cause.

4. Increasing Fungal Trends Were Not Adequately Addressed

FDA noted an increasing trend of fungal recoveries in aseptic production areas and supporting cleanrooms. The concern was not limited to individual environmental monitoring excursions.

FDA was concerned about the overall trend and the fact that investigations were closed without sufficiently robust CAPA. A proper environmental monitoring trend program should evaluate:

Organism identification
Location
Frequency
Recurrence
Severity
Personnel association
Equipment association
Room association
Seasonal trends
Alert/action-level excursions
Repeated recoveries
Microbial species distribution

Trending should be performed proactively rather than waiting for a sterility failure.

5. Inadequate CAPA Program

The FDA Warning Letter found that the firm’s investigations frequently did not lead to sufficiently effective corrective and preventive actions. A strong CAPA program should include:

Problem definition
Immediate correction
Investigation
Root-cause analysis
Risk assessment
Corrective action
Preventive action
Implementation
Effectiveness verification
Management review
Quality Unit approval

CAPA should address systemic causes rather than simply updating an SOP or retraining employees.

For example, if recurring fungal contamination is associated with facility design, HVAC performance, personnel movement, equipment condition, or cleaning practices, retraining alone would not adequately address the problem.

6. Independent Assessment of the Investigation System

FDA requested a comprehensive independent assessment of the firm’s systems for investigating:

Deviations
Discrepancies
Complaints
OOS results
Batch failures
Sterility failures
Environmental monitoring excursions

The assessment should evaluate:

Investigation competency
Investigation scope
Root-cause methodology
Evidence evaluation
Risk assessment
CAPA selection
CAPA effectiveness
Quality Unit oversight
Investigation timelines
Documentation practices
Trend analysis

This requirement demonstrates the importance of having a scientifically robust investigation process.

7. Comprehensive Contamination Risk Assessment

FDA requested an independent risk assessment covering contamination hazards associated with aseptic manufacturing. The assessment should include:

ISO 5 operations
Human interventions
Equipment suitability
Equipment ergonomics
Air quality
Air volume
Airflow
Facility layout
Personnel flow
Material flow
Material transfer
Cleanroom design
Aseptic processing lines

The assessment should lead to specific CAPA recommendations and defined implementation timelines.

8. Environmental Monitoring Program Deficiencies

Environmental monitoring was another major concern identified in the FDA Warning Letter.

FDA determined that the facility’s environmental monitoring system had deficiencies involving sampling techniques and sampling locations.

For example, investigators observed that certain surfaces were not adequately sampled and that analysts did not sample the maximum accessible areas.

This is important because environmental monitoring data are only meaningful when samples are collected using scientifically appropriate methods.

9. Effective Environmental Monitoring Requires a Risk-Based Strategy

An effective EM program should define:

Sampling Locations

Locations should be selected based on contamination risk, including:

Critical processing areas
Product-contact surfaces
Equipment
Operator interaction points
Difficult-to-clean areas
Material transfer points
Airflow-sensitive areas

Sampling Frequency

The frequency should be scientifically justified based on:

Process risk
Historical data
Facility classification
Product exposure
Intervention frequency
Environmental trends

Sampling Methods

Methods should be appropriately qualified and performed consistently.

10. Quality Unit Oversight Deficiencies

The second major violation cited in the FDA Warning Letter involved the Quality Control Unit under 21 CFR 211.22(d).

FDA found that the Quality Unit did not provide adequate oversight of sterile manufacturing operations. Specific deficiencies included:

Inadequate documentation of aseptic interventions
Inadequate disinfectant efficacy studies
Lack of appropriate process validation
Insufficient review of manufacturing records
Inadequate oversight of manufacturing activities

The Quality Unit must have sufficient authority and resources to ensure that manufacturing and laboratory activities comply with approved procedures and CGMP requirements.

11. Incomplete Documentation of Aseptic Interventions

FDA investigators observed significant discrepancies between the number of interventions actually performed and the number documented in batch records.

One batch record reportedly documented only 12 interventions, while approximately 200 interventions were indicated to have occurred. Critical interventions were also not adequately documented.

These included activities such as:

Removing vials from filling areas
Handling fallen vials
Other interventions within critical processing areas

Accurate documentation of aseptic interventions is essential because interventions can potentially affect sterility assurance.

12. Why Aseptic Intervention Documentation Matters

Aseptic interventions should be:

Clearly defined
Minimized where possible
Documented contemporaneously
Scientifically assessed
Included in aseptic process simulations where appropriate
Evaluated for contamination risk
Reviewed by the Quality Unit

Incomplete documentation compromises the ability to determine whether a batch was manufactured under validated and controlled conditions.

13. Disinfectant Efficacy Study Deficiencies

FDA also identified deficiencies in disinfectant efficacy studies. The firm’s studies did not adequately represent the full range of microorganisms recovered from the facility.

A scientifically robust disinfectant efficacy program should consider relevant environmental isolates and demonstrate that the selected disinfectant system is effective under defined conditions. Important factors include:

Organism selection
Contact time
Concentration
Surface type
Temperature
Organic load
Application method
Recovery methodology
Neutralization
Environmental conditions

The FDA Warning Letter therefore highlights the importance of connecting environmental monitoring data with disinfectant efficacy studies.

14. Process Validation Deficiencies

FDA also identified concerns regarding process validation. The firm had implemented a new production step but had not adequately demonstrated process validation for the revised manufacturing process.

For sterile drug products, process validation should provide evidence that the process can consistently produce a product meeting predetermined quality requirements. Important elements include:

Process design
Process qualification
Process Performance Qualification (PPQ)
Critical process parameters
Critical quality attributes
Intra-batch variation
Inter-batch variation
Continued process verification
Ongoing monitoring

15. Cleaning Validation Deficiencies

The FDA Warning Letter also required improvements to the cleaning validation program. A comprehensive cleaning validation program should consider worst-case conditions. FDA specifically highlighted the importance of evaluating:

Higher toxicity products
Higher potency products
Poorly soluble products
Difficult-to-clean products
Difficult-to-clean equipment locations
Worst-case swab locations
Maximum dirty hold time
Cleaning-agent effectiveness
Maximum clean hold time where applicable

Cleaning validation should demonstrate that residues and contaminants are consistently controlled to scientifically justified acceptance criteria.

16. Change Management and Validation

The warning letter also emphasized the importance of change control. Before introducing:

New equipment
New manufacturing steps
New products
Process modifications
Facility modifications
HVAC changes
Critical equipment modifications

the firm should perform appropriate:

Change control
Impact assessment
Quality risk assessment
Validation impact assessment
Qualification assessment
Regulatory assessment
Implementation
Post-implementation verification

A change should not be assumed to have no validation impact merely because it appears minor.

17. Airflow Visualization Smoke Study Deficiencies

Another significant finding in the FDA Warning Letter involved airflow visualization (AFV) smoke studies.

FDA found that smoke studies were not adequately performed following modifications to a Restricted Access Barrier System (RABS).

The validation group reportedly determined that smoke studies were unnecessary after a modification, even though engineering personnel had proposed performing them.

FDA considered this inadequate because modifications to critical airflow systems must be evaluated to determine their potential effect on airflow and first-air protection.

18. Dynamic Smoke Studies Are Critical for Sterile Manufacturing

Airflow visualization studies should demonstrate that unidirectional airflow provides appropriate protection during both normal operations and interventions. Studies should consider:

Normal operation
Operator interventions
Equipment adjustments
Product spillage response
Line stoppages
Material movement
Cleaning interventions
Worst-case conditions

The purpose is to demonstrate that interventions do not compromise first-air protection. The FDA Warning Letter also highlighted the importance of performing studies under dynamic conditions using appropriate visualization techniques.

19. RABS Design and Operation Concerns

FDA also questioned whether the facility’s processing lines met the expected characteristics of a Restricted Access Barrier System. The agency noted concerns regarding the number of interventions and the actual design and operation of the system.

A barrier system should reduce the possibility of direct human intervention and minimize contamination risks. Sterile manufacturing facilities should therefore assess:

Barrier integrity
Glove systems
Material transfer
Intervention frequency
Operator access
Airflow
Cleaning
Disinfection
Equipment ergonomics
Line design

20. Facility Maintenance Deficiencies

The inspection identified deterioration in classified areas. Examples included:

Peeling paint
Bubbling surfaces
Plastic debris
Deteriorating surfaces
Cleanroom maintenance deficiencies

Deteriorating surfaces can become sources of:

Particulate contamination
Microbial contamination
Fungal growth
Cleaning difficulties

The FDA Warning Letter therefore reinforces the importance of maintaining cleanrooms in an appropriate state of repair.

21. Contamination Control Strategy

A modern sterile manufacturing operation should maintain an integrated contamination control strategy. The strategy should consider:

Personnel

Gowning
Training
Qualification
Aseptic behavior
Personnel flow

Facility

Cleanroom classification
HVAC
Airflow
Pressure differentials
Surfaces
Maintenance

Equipment

Design
Cleanability
Sterilizability
Maintenance
Preventive maintenance

Materials

Material transfer
Disinfection
Storage
Movement

Process

Interventions
Aseptic operations
Sterilization
Filling
Hold times

Monitoring

Environmental monitoring
Personnel monitoring
Trending
Microbial identification

22. Pharmaceutical Quality System Was Considered Ineffective

The FDA Warning Letter concluded that significant findings demonstrated deficiencies in the overall pharmaceutical quality system. The concerns included:

Inadequate management oversight
Insufficient Quality Unit authority
Weak investigations
Inadequate CAPA
Environmental monitoring deficiencies
Poor aseptic practices
Validation deficiencies
Facility maintenance problems
Inadequate contamination control

FDA therefore expected executive management to conduct a comprehensive assessment of global manufacturing operations.

23. Independent GMP Consultant Recommended

Because of the nature and scope of the deficiencies, FDA recommended that the firm engage a qualified consultant in accordance with 21 CFR 211.34. The consultant should assist with:

CGMP compliance
Investigation remediation
CAPA
Contamination control
Quality systems
Validation
Facility assessment
Manufacturing systems
Laboratory systems

FDA also recommended a comprehensive six-system GMP audit and evaluation of CAPA completion and effectiveness. Importantly, hiring a consultant does not transfer regulatory responsibility away from company management. Executive management remains responsible for CGMP compliance.

24. What Pharmaceutical Companies Can Learn from This FDA Warning Letter

This FDA Warning Letter provides several important lessons for sterile pharmaceutical manufacturers.

Lesson 1: Sterility Failures Require Deep Investigations

A failed sterility test should never automatically be classified as an isolated event or assigned an “undetermined” root cause without comprehensive evaluation.

Lesson 2: Recurring Fungal Recoveries Require Systemic Investigation

Repeated fungal contamination should trigger a comprehensive assessment of facility, HVAC, personnel, equipment, cleaning, disinfection, and material flow.

Lesson 3: CAPA Must Address Root Causes

Retraining and SOP revisions may be necessary but are not always sufficient.

Lesson 4: Environmental Monitoring Must Be Scientifically Designed

Sampling location, frequency, technique, organism identification, and trending are all critical.

Lesson 5: Smoke Studies Must Reflect Actual Operations

Dynamic interventions should be evaluated during airflow visualization studies.

Lesson 6: Quality Units Must Have Authority

The Quality Unit must be capable of independently reviewing, approving, and controlling critical GMP activities.

Lesson 7: Batch Records Must Reflect Actual Operations

Every significant aseptic intervention should be appropriately documented.

Lesson 8: Facility Condition Is Part of Contamination Control

Peeling paint, damaged surfaces, debris, and poor maintenance can contribute to contamination risk.

Lesson 9: Validation Must Follow Process Changes

New equipment, process steps, or facility modifications should undergo appropriate change control and validation-impact assessment.

Lesson 10: Management Oversight Is Essential

Systemic GMP failures generally require executive-management involvement and adequate allocation of technical and financial resources.

FDA Warning Letter: QA and GMP Audit Checklist

Pharmaceutical manufacturers can use the following questions for internal self-assessment:

Investigations

Are sterility failures thoroughly investigated?
Are environmental monitoring excursions scientifically investigated?
Is root cause supported by objective evidence?
Are recurring trends evaluated?
Is CAPA effectiveness verified?

Environmental Monitoring

Are sampling locations risk-based?
Are sampling techniques validated or appropriately qualified?
Are all critical surfaces adequately monitored?
Are fungal trends evaluated?
Are microorganisms identified appropriately?
Are adverse trends investigated?

Aseptic Processing

Are interventions minimized?
Are interventions documented?
Are operators properly qualified?
Is first-air protection maintained?
Are dynamic smoke studies performed?
Are worst-case interventions included?

Quality Unit

Does the QU have adequate authority?
Does the QU review every batch appropriately?
Does the QU approve investigations and CAPA?
Is management providing sufficient resources?

Validation

Is process performance qualification completed?
Is continued process verification established?
Are equipment and facilities qualified?
Are changes assessed for validation impact?
Are cleaning validation worst cases scientifically justified?

Facility

Are cleanroom surfaces intact?
Is preventive maintenance effective?
Are HVAC systems appropriately controlled?
Are personnel and material flows appropriate?
Are contamination hazards periodically reassessed?

Conclusion

This FDA Warning Letter highlights serious weaknesses in sterile pharmaceutical manufacturing involving sterility failure investigations, fungal contamination, environmental monitoring, CAPA, Quality Unit oversight, aseptic interventions, airflow visualization, RABS operation, process validation, cleaning validation, facility maintenance, and contamination control.

The central regulatory lesson is that sterile manufacturing requires an integrated and scientifically justified quality system.

A pharmaceutical manufacturer cannot rely solely on final sterility testing to demonstrate product quality. Sterility assurance must be built into the entire manufacturing process through facility design, qualified equipment, validated processes, effective cleaning and disinfection, environmental monitoring, trained personnel, robust investigations, effective CAPA, and strong Quality Unit oversight.

For companies supplying the U.S., UK, European Union, and other regulated markets, the FDA Warning Letter is an important reminder to conduct proactive GMP gap assessments before regulatory inspections identify systemic deficiencies.

The most effective approach is to establish a continuous state of control supported by Quality Risk Management (QRM), contamination control strategy, process validation, environmental monitoring, data integrity, CAPA effectiveness, and management review.

Reference Warning Letter Date – 08/27/2026 Issued to Jabil Inc. for CGMP/Finished Pharmaceuticals/Adulterated by the Center for Drug Evaluation and Research (CDER)

Disclaimer

Educational & Awareness Purpose Only:
This article has been prepared for learning, training, educational, and pharmaceutical industry awareness purposes only. The information presented in this article is based on and/or summarized from publicly available information published on the official U.S. Food and Drug Administration (FDA) website, including FDA Warning Letters.

For the original and most up-to-date information, readers should refer directly to the official FDA Warning Letters database and related FDA publications.

This article is not an official FDA publication, communication, guidance, regulatory decision, or statement of the U.S. Food and Drug Administration. PharmGuidances is not affiliated with, endorsed by, or representing the FDA.

The information provided should not be used as a substitute for official FDA documents, applicable laws and regulations, regulatory guidance, legal advice, compliance advice, or professional consultation. It should not be relied upon for making regulatory, legal, manufacturing, quality, or business decisions.

Official Reference:
FDA Warning Letters – U.S. Food and Drug Administration

Post Views: 5